[{"id":"53a3393c-70b7-4bcc-a8e3-5120097c6768","acronym":"OVELIA","url":"https://clinicaltrials.gov/study/NCT04906395","created_at":"2021-05-28T13:52:36.773Z","updated_at":"2025-02-25T12:28:09.357Z","phase":"Phase 3","brief_title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","source_id_and_acronym":"NCT04906395 - OVELIA","lead_sponsor":"Tolmar Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-24"},{"id":"198522b7-100a-4569-a5b1-c2c7d2835c3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06195306","created_at":"2024-01-08T16:17:49.869Z","updated_at":"2025-02-25T13:42:01.381Z","phase":"Phase 2","brief_title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","source_id_and_acronym":"NCT06195306","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FOXA1 • AGR2 • LEP","pipe":"","alterations":" ","tags":["FOXA1 • AGR2 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-21"},{"id":"251108c9-4fb9-4d2a-b2b3-ca1b2c0bb048","acronym":"","url":"https://clinicaltrials.gov/study/NCT01273168","created_at":"2021-01-18T05:09:01.740Z","updated_at":"2025-02-25T13:39:00.081Z","phase":"Phase 1","brief_title":"Endoxifen in Adults With Hormone Receptor Positive Solid Tumors","source_id_and_acronym":"NCT01273168","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"907c18db-1f38-4071-a1e3-b3af86377f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05941520","created_at":"2023-07-12T16:10:13.477Z","updated_at":"2025-02-25T13:49:53.635Z","phase":"Phase 2","brief_title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","source_id_and_acronym":"NCT05941520","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • acolbifene"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/23/2024","start_date":" 08/23/2024","primary_txt":" Primary completion: 08/23/2027","primary_completion_date":" 08/23/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-21"},{"id":"909260a0-1d22-47e9-9081-eb961f7d0511","acronym":"","url":"https://clinicaltrials.gov/study/NCT06184750","created_at":"2023-12-28T15:17:32.895Z","updated_at":"2025-02-25T13:42:00.077Z","phase":"Phase 2","brief_title":"Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","source_id_and_acronym":"NCT06184750","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ADAR","pipe":"","alterations":" ","tags":["ADAR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/27/2024","start_date":" 09/27/2024","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-21"},{"id":"7e70ebdc-cdaa-4580-9eb1-432961d43354","acronym":"CAMBRIA-2","url":"https://clinicaltrials.gov/study/NCT05952557","created_at":"2023-07-20T14:08:53.643Z","updated_at":"2025-02-25T14:18:07.526Z","phase":"Phase 3","brief_title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","source_id_and_acronym":"NCT05952557 - CAMBRIA-2","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 5500","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 03/04/2030","primary_completion_date":" 03/04/2030","study_txt":" Completion: 05/06/2037","study_completion_date":" 05/06/2037","last_update_posted":"2025-02-18"},{"id":"ea690cf4-a21c-4998-8096-bc622dfec937","acronym":"GeparPiPPa","url":"https://clinicaltrials.gov/study/NCT05306041","created_at":"2022-03-31T16:52:51.318Z","updated_at":"2025-02-25T14:16:47.877Z","phase":"Phase 2","brief_title":"Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer","source_id_and_acronym":"NCT05306041 - GeparPiPPa","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • PGR positive","tags":["HER-2 • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 01/02/2023","start_date":" 01/02/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-17"},{"id":"086bd3e8-00e3-4652-8096-301cc6035c9e","acronym":"INAVO122","url":"https://clinicaltrials.gov/study/NCT05894239","created_at":"2023-06-09T09:09:03.004Z","updated_at":"2025-02-25T14:42:07.222Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05894239 - INAVO122","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 07/28/2023","start_date":" 07/28/2023","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 12/28/2032","study_completion_date":" 12/28/2032","last_update_posted":"2025-02-14"},{"id":"e8ce3ccf-c1c8-4ee0-b8b5-f9d8061d44e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00667121","created_at":"2021-01-18T02:29:16.873Z","updated_at":"2025-02-25T14:39:15.807Z","phase":"","brief_title":"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline","source_id_and_acronym":"NCT00667121","lead_sponsor":"Mayo Clinic","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 03/16/2011","start_date":" 03/16/2011","primary_txt":" Primary completion: 05/12/2014","primary_completion_date":" 05/12/2014","study_txt":" Completion: 05/27/2014","study_completion_date":" 05/27/2014","last_update_posted":"2025-02-14"},{"id":"db930c87-92ac-41c5-ad78-232d08feae0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00949598","created_at":"2021-01-18T03:41:34.600Z","updated_at":"2025-02-25T14:48:25.058Z","phase":"Phase 3","brief_title":"Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer","source_id_and_acronym":"NCT00949598","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" ER • PCNA","pipe":" | ","alterations":" ER positive","tags":["ER • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 10/01/2010","study_completion_date":" 10/01/2010","last_update_posted":"2025-02-13"},{"id":"89c18e67-5d9f-4f4c-836e-d176238b546e","acronym":"CAMBRIA-1","url":"https://clinicaltrials.gov/study/NCT05774951","created_at":"2023-03-20T20:03:21.727Z","updated_at":"2025-02-25T15:20:21.062Z","phase":"Phase 3","brief_title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","source_id_and_acronym":"NCT05774951 - CAMBRIA-1","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 4300","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 04/20/2027","primary_completion_date":" 04/20/2027","study_txt":" Completion: 05/29/2036","study_completion_date":" 05/29/2036","last_update_posted":"2025-02-11"},{"id":"996991a4-16ed-4414-90f1-2f630a1b4a1d","acronym":"lidERA Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04961996","created_at":"2021-07-14T14:53:31.141Z","updated_at":"2025-02-25T15:35:10.567Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","source_id_and_acronym":"NCT04961996 - lidERA Breast Cancer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Verzenio (abemaciclib) • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 4200","initiation":"Initiation: 08/27/2021","start_date":" 08/27/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 11/21/2033","study_completion_date":" 11/21/2033","last_update_posted":"2025-02-10"},{"id":"d32e8658-c9d2-4f04-9c89-06bcade2de1e","acronym":"RxPONDER","url":"https://clinicaltrials.gov/study/NCT01272037","created_at":"2021-01-18T05:08:42.199Z","updated_at":"2025-02-25T16:36:08.722Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","source_id_and_acronym":"NCT01272037 - RxPONDER","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5018","initiation":"Initiation: 01/15/2011","start_date":" 01/15/2011","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-02-06"},{"id":"432f1e5f-02a6-4552-b299-64f4b470c25a","acronym":"heredERA","url":"https://clinicaltrials.gov/study/NCT05296798","created_at":"2022-04-20T16:53:29.043Z","updated_at":"2025-02-25T12:28:43.790Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","source_id_and_acronym":"NCT05296798 - heredERA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • EGFR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • tamoxifen • Perjeta (pertuzumab) • giredestrant (RG6171) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 922","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-04"},{"id":"4de118f4-f565-48f1-9ed6-83996e6bbbe2","acronym":"DEBRA","url":"https://clinicaltrials.gov/study/NCT04852887","created_at":"2021-04-21T11:53:33.835Z","updated_at":"2025-02-25T16:53:39.381Z","phase":"Phase 3","brief_title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","source_id_and_acronym":"NCT04852887 - DEBRA","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1670","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2041","study_completion_date":" 07/01/2041","last_update_posted":"2025-02-04"},{"id":"65c1ec6b-055f-4603-b88a-18648345da78","acronym":"EMPRESS","url":"https://clinicaltrials.gov/study/NCT05659563","created_at":"2022-12-21T15:59:16.652Z","updated_at":"2025-02-25T16:54:37.319Z","phase":"Phase 2","brief_title":"Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] \u0026 Ki67≥10%","source_id_and_acronym":"NCT05659563 - EMPRESS","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • giredestrant (RG6171) • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-04"},{"id":"fbf3716a-0c89-444d-8fe3-c713df6342b5","acronym":"RaPhLRR","url":"https://clinicaltrials.gov/study/NCT05467891","created_at":"2022-07-21T12:57:26.496Z","updated_at":"2025-02-25T15:54:32.807Z","phase":"Phase 2","brief_title":"Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05467891 - RaPhLRR","lead_sponsor":"Oana Danciu","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-01-31"},{"id":"b411be81-667e-4173-a340-a9d384984b56","acronym":"EUROPA","url":"https://clinicaltrials.gov/study/NCT04134598","created_at":"2021-01-18T20:11:54.546Z","updated_at":"2025-02-25T17:30:03.177Z","phase":"Phase 3","brief_title":"ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer","source_id_and_acronym":"NCT04134598 - EUROPA","lead_sponsor":"Azienda Ospedaliero-Universitaria Careggi","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 926","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 04/08/2025","primary_completion_date":" 04/08/2025","study_txt":" Completion: 04/08/2030","study_completion_date":" 04/08/2030","last_update_posted":"2025-01-30"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"cbfdb786-2bdb-4bd6-ab84-5ea52effef85","acronym":"EMBER-4","url":"https://clinicaltrials.gov/study/NCT05514054","created_at":"2022-08-24T21:07:46.773Z","updated_at":"2025-02-25T16:18:06.124Z","phase":"Phase 3","brief_title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","source_id_and_acronym":"NCT05514054 - EMBER-4","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 03/01/2032","study_completion_date":" 03/01/2032","last_update_posted":"2025-01-22"},{"id":"ea16c3dc-6884-43c3-8786-5858a4804bcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04024462","created_at":"2021-01-18T19:45:27.762Z","updated_at":"2025-02-25T12:27:15.491Z","phase":"Phase 3","brief_title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","source_id_and_acronym":"NCT04024462","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PIK3CA","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/05/2020","start_date":" 02/05/2020","primary_txt":" Primary completion: 12/13/2021","primary_completion_date":" 12/13/2021","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2024-12-20"},{"id":"25a4e8fa-1698-459b-bd19-1f109f35e7bd","acronym":"TRAK-ER","url":"https://clinicaltrials.gov/study/NCT04985266","created_at":"2021-08-02T14:53:00.458Z","updated_at":"2025-02-25T15:00:01.624Z","phase":"Phase 2","brief_title":"A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04985266 - TRAK-ER","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 03/30/2022","start_date":" 03/30/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-12-05"},{"id":"79775896-981f-4795-860c-5b8a8ca129f9","acronym":"ADEPT","url":"https://clinicaltrials.gov/study/NCT04569747","created_at":"2021-01-18T21:49:27.045Z","updated_at":"2025-02-25T12:27:45.281Z","phase":"Phase 2","brief_title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","source_id_and_acronym":"NCT04569747 - ADEPT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 375","initiation":"Initiation: 01/11/2021","start_date":" 01/11/2021","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-10-01"},{"id":"072b5222-7280-4f30-8150-3b6f5d947d3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02228681","created_at":"2024-01-03T20:17:23.392Z","updated_at":"2025-02-25T15:41:52.541Z","phase":"Phase 2","brief_title":"Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer","source_id_and_acronym":"NCT02228681","lead_sponsor":"GOG Foundation","biomarkers":" PIK3CA • PGR • PTEN • CTNNB1","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation","tags":["PIK3CA • PGR • PTEN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 05/21/2015","start_date":" 05/21/2015","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 08/22/2024","study_completion_date":" 08/22/2024","last_update_posted":"2024-09-19"}]